Syner-G BioPharma Group, a provider of consulting services to pharmaceutical and biotechnology clients, has named Ron Kraus Chief Executive Officer.
 
Mr. Kraus has more than 25 years of experience leading life sciences companies, including global responsibility for customer strategy, sales, operations, and various support functions. Prior to rejoining Syner-G, Ron was Chief Operating Officer at Cytel where he contributed to the growth and enhanced profitability of their Services business. Mr. Kraus also spent two decades at Parexel International in roles of increasing responsibility. During his tenure as the Global Head of Parexel Consulting, a product development consultancy, he led the development and execution of a strategy that drove robust expansion and launched new services, both through organic growth and strategic acquisitions. 
 
Mr. Kraus succeeds Syner-G’s founder, Prabu Nambiar, PhD, MBA, RAC, as CEO. Dr. Nambiar will continue his work at Syner-G with a focus on clients, corporate strategy, and promoting business growth. Dr. Nambiar led Syner-G through a rapid growth phase, including the late 2021 acquisition of Impact Pharmaceutical Services, a medical writing, regulatory strategy, and regulatory publishing provider.
 
Dr. Nambiar said, “I couldn’t be more excited and pleased to welcome Ron to the Syner-G family. To meet our future strategic needs, we were very rigorous in our search for our next CEO, and I am extremely confident that Ron is the right person, at the right time, to lead Syner-G in its mission to become the preeminent provider of pharmaceutical consulting services worldwide.”
 
“I am humbled to be chosen to lead this extraordinary organization into the future,” Mr. Kraus said. “And I thank Prabu and all of the Syner-G team for the excellent foundation that they’ve established. Syner-G has experienced strong growth, underpinned by high quality services and a reputation for scientific excellence. I see the immense potential of what this team has created, and I am inspired by the collaboration and hard work that’s been invested. I am looking forward to working with this talented team and am committed to being a good steward of that investment.”